Additional western blotting experiments were performed to verify the aberrant expression of IL-17D in these lung cancer cell lines; IL-17D was expressed at low or undetectable levels in HBECs and some NSCLC cell lines (H460, HCC827 and A549) but was highly expressed in all SCLC cell lines and H1155, an NSCLC cell line with neuroendocrine features (Figure 1C). The gene discussed is IL17D; the disease is lung carcinoma.